Companies: 10,795·Total market cap: $144.5T
Impel Pharmaceuticals Inc.

Impel Pharmaceuticals Inc.

IMPLNASDAQHealthcare
$0.04
$-0.02(-27.27%)
Market Cap$956000
P/E Ratio—
52W High$4.2
52W Low$0.0212
Overview

Impel Pharmaceuticals Inc. (IMPL) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001445499 · IMPL · NASDAQ · as of Jun 9, 2026

Filing snapshot

206
Total Filings
4
Latest Form
2024-04-09
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001445499 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2023-03-31
Fiscal Year End
Mar 31, 2023
Accession No.
0000950170-23-011398
Primary Document
impl-20221231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001445499 · Accession 0000950170-23-011398

Latest Key Filings

10-QQuarterly Report
10-Q
2023-11-14
View 10-Q on SEC
8-KCurrent Report
8-K
2024-03-12Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
15-12G15-12G
15-12G
2024-03-26
View
8-KCurrent Report
8-K
2024-03-12
View
EFFECTEFFECT
EFFECT
2024-02-15
View
S-8 POSS-8 POS
S-8 POS
2024-02-14
View
S-8 POSS-8 POS
S-8 POS
2024-02-14
View
S-8 POSS-8 POS
S-8 POS
2024-02-14
View
POS AMPOS AM
POS AM
2024-02-14
View
8-KCurrent Report
8-K
2024-02-14
View
8-KCurrent Report
8-K
2024-01-02
View
25-NSE25-NSE
25-NSE
2023-12-27
View
3Initial Statement of Beneficial Ownership
FORM 3 SUBMISSION
2023-12-26
View
8-KCurrent Report
8-K
2023-12-20
View
8-KCurrent Report
8-K
2023-12-18
View
SC 13D/ASC 13D/A
SC 13D/A
2023-12-04
View
8-KCurrent Report
8-K
2023-12-04
View
Showing 1–15 of 146 filingsForm 4 / 144 hidden· 206 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001445499  |  Exchange: NASDAQ · Healthcare

Impel Pharmaceuticals Inc. (NASDAQ: IMPL) has submitted 206 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001445499, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Impel Pharmaceuticals Inc.'s most comprehensive regulatory disclosure. The most recent Impel Pharmaceuticals Inc. 10-K was filed on 2023-03-31 for fiscal year ending 2023. Historical IMPL 10-K annual reports are available from 2008 through 2023.

Investors researching Impel Pharmaceuticals Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
CWBR SEC Filings →TMBR SEC Filings →CYTO SEC Filings →NVIV SEC Filings →AXDX SEC Filings →ACOR SEC Filings →BLCM SEC Filings →INFIQ SEC Filings →
→ IMPL Financials→ IMPL Earnings→ IMPL Insider Trades

Frequently Asked Questions

IMPL SEC Filings · 8 questions

Impel Pharmaceuticals Inc. (IMPL) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 206 filings and access original documents at no cost. Impel Pharmaceuticals Inc.'s CIK is 0001445499.

IMPL SEC filingsImpel Pharmaceuticals Inc. SEC documentsfind IMPL 10-K